Point72 Asset Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54.3M Buy
1,410,826
+583,301
+70% +$21.5M 0.07% 333
2025
Q4
$29.4M Sell
827,525
-410,308
-33% -$11.5M 0.03% 671
2025
Q3
$17.8M Sell
1,237,833
-3,674,091
-75% -$43.5M 0.03% 601
2025
Q2
$35.3M Sell
4,911,924
-383,621
-7% -$2.13M 0.07% 324
2025
Q1
$31.7M Sell
5,295,545
-51,757
-1% -$406K 0.07% 319
2024
Q4
$41.7M Sell
5,347,302
-5,123,096
-49% -$51.1M 0.09% 256
2024
Q3
$113M Hold
10,470,398
0.29% 71
2024
Q2
$88.3M Buy
10,470,398
+3,794,150
+57% +$28.8M 0.23% 115
2024
Q1
$44.9M Buy
6,676,248
+1,484,800
+29% +$9.18M 0.11% 225
2023
Q4
$30.5M Buy
5,191,448
+1,424,693
+38% +$10.9M 0.07% 316
2023
Q3
$36.7M Sell
3,766,755
-918,299
-20% -$10.9M 0.11% 244
2023
Q2
$55.5M Buy
4,685,054
+2,448,354
+109% +$28.1M 0.17% 161
2023
Q1
$24.1M Buy
+2,236,700
New +$28.6M 0.07% 298
2022
Q4
Sell
-357,200
Closed -$5.33M 1546
2022
Q3
$5.33M Buy
+357,200
New +$4.9M 0.02% 702
2022
Q2
Sell
-853,451
Closed -$6.39M 1430
2022
Q1
$6.39M Sell
853,451
-13,449
-2% -$93.7K 0.03% 634
2021
Q4
$7.44M Sell
866,900
-138,403
-14% -$1.2M 0.03% 586
2021
Q3
$8.46M Sell
1,005,303
-477,792
-32% -$3.66M 0.04% 530
2021
Q2
$12M Buy
1,483,095
+871,595
+143% +$7.36M 0.05% 406
2021
Q1
$5.37M Buy
611,500
+206,500
+51% +$1.99M 0.03% 554
2020
Q4
$4.55M Buy
+405,000
New +$4.45M 0.02% 597
2018
Q3
Sell
-37,500
Closed -$2.15M 1032
2018
Q2
$2.15M Sell
37,500
-43,475
-54% -$2.09M 0.01% 742
2018
Q1
$3.6M Buy
+80,975
New +$3.6M 0.02% 643

Other funds holding COGT

Point72 Asset Management's COGT Position: Q1 2026 in Review

Point72 Asset Management increased its Cogent Biosciences (COGT) stake by 70% in Q1 2026, buying an estimated $21.5M and bringing the position to 1,410,826 shares worth $54.3M. The position accounts for 0.07% of the portfolio, ranked #333.

Point72 Asset Management first reported a position in COGT in Q1 2018 and has held it in 22 quarters since. The position peaked at $113M in Q3 2024. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Point72 Asset Management held 1,410,826 shares of Cogent Biosciences worth $54.3M as of Q1 2026.
  • Point72 Asset Management bought 583,301 Cogent Biosciences shares in Q1 2026, an estimated $21.5M.
  • Cogent Biosciences made up 0.07% of Point72 Asset Management's portfolio in Q1 2026, its #333 holding.
  • Point72 Asset Management first reported a position in Cogent Biosciences in Q1 2018 and has held it in 22 quarters since.
  • Point72 Asset Management's Cogent Biosciences position peaked at $113M in Q3 2024.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.